The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Please provide your email address to receive an email when new articles are posted on . The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...
Please provide your email address to receive an email when new articles are posted on . Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...
NEW YORK (Reuters Health) - Subcutaneous daratumumab could offer an effective and more convenient alternative to the intravenous formulation for patients with relapsed or refractory multiple myeloma, ...
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results